Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Pembrolizumab |
| Indication/Tumor Type | stomach cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | stomach cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with platinum and fluoropyrimidine-based chemotherapy is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for patients with ERBB2 (HER2)-negative, metastatic gastric cancer with CD274 (PD-L1) expression, especially for those with higher levels of tumor CD274 (PD-L1) expression (PMID: 38458658; ESMO.org). | detail... 38458658 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| ESMO Clinical Practice Guidelines | Full reference... | |
| (38458658) | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. | Full reference... |